<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163994</url>
  </required_header>
  <id_info>
    <org_study_id>MEM-0510</org_study_id>
    <nct_id>NCT01163994</nct_id>
  </id_info>
  <brief_title>Antibiotic Treatment of Multiple Erythema Migrans</brief_title>
  <official_title>Comparison of Ceftriaxone and Doxycycline for Treatment of Multiple Erythema Migrans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of 15-day ceftriaxone versus
      15-day doxycycline treatment in patients with multiple erythema migrans.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients treated for multiple erythema migrans with ceftriaxone or doxycycline for 15 days.</measure>
    <time_frame>enrolling 3 years, 1 year follow-up for individual participant: first assessment at baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients treated for multiple erythema migrans with ceftriaxone or doxycycline for 15 days.</measure>
    <time_frame>second assessment at 14 days postenrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients treated for multiple erythema migrans with ceftriaxone or doxycycline for 15 days.</measure>
    <time_frame>third assessment at 2 months postenrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients treated for multiple erythema migrans with ceftriaxone or doxycycline for 15 days.</measure>
    <time_frame>fourth assessment at 6 months postenrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients treated for multiple erythema migrans with ceftriaxone or doxycycline for 15 days.</measure>
    <time_frame>fifth assessment at 12 months postenrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, or irritability between patients treated with antibiotic for multiple erythema migrans and control subjects without a history of Lyme borreliosis.</measure>
    <time_frame>enrolling 3 years, 1 year follow-up for individual participant: first assessment at baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients with solitary versus multiple erythema migrans after antibiotic treatment.</measure>
    <time_frame>enrolling 3 years, 1 year follow-up for individual participant: at baseline and at 14 days, 2, 6, and 12 months thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, or irritability between patients treated with antibiotic for multiple erythema migrans and control subjects without a history of Lyme borreliosis.</measure>
    <time_frame>second assessment at 6 months postenrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, or irritability between patients treated with antibiotic for multiple erythema migrans and control subjects without a history of Lyme borreliosis.</measure>
    <time_frame>third assessment at 6 months postenrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients with solitary versus multiple erythema migrans after antibiotic treatment.</measure>
    <time_frame>second assessment at 14 days postenrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients with solitary versus multiple erythema migrans after antibiotic treatment.</measure>
    <time_frame>third assessment at 2 months postenrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients with solitary versus multiple erythema migrans after antibiotic treatment.</measure>
    <time_frame>fourth assessment at 6 months postenrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective sequelae and post-treatment subjective symptoms such as fatigue, malaise, arthralgias, headache, myalgias, paresthesias, dizziness, or irritability in patients with solitary versus multiple erythema migrans after antibiotic treatment.</measure>
    <time_frame>fifth assessment at 12 months postenrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Multiple Erythema Migrans</condition>
  <arm_group>
    <arm_group_label>MEM-ceftriaxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MEM-doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>EM-doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftriaxone</intervention_name>
    <description>intravenously, 2 g, qd, 15 days</description>
    <arm_group_label>MEM-ceftriaxone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline</intervention_name>
    <description>orally, 100 mg, bid, 15 days</description>
    <arm_group_label>MEM-doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>erythema migrans patients treated with doxycycline</intervention_name>
    <description>orally, 100 mg, bid, 15 days</description>
    <arm_group_label>EM-doxycycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  multiple erythema migrans in patients &gt; 15 years

        Exclusion Criteria:

          -  a history of Lyme borreliosis in the past

          -  pregnancy or lactation

          -  immunocompromised status

          -  serious adverse event to doxycycline or beta lactam antibiotic

          -  taking antibiotic with antiborrelial activity within 10 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franc Strle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Ljubljana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dasa Stupica, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Ljubljana, Department of Infectious Diseases Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dasa Stupica, MD</last_name>
    <phone>+386 1 522 2110</phone>
    <email>cerar.dasa@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franc Strle, MD</last_name>
    <phone>+386 1 522 2610</phone>
    <email>franc.strle@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMC Ljubljana, Department of Infectious Diseases</name>
      <address>
        <city>Ljubljana</city>
        <zip>1525</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dasa Stupica, MD</last_name>
      <phone>+386 1 522 2110</phone>
      <email>cerar.dasa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Franc Strle, MD</last_name>
      <phone>+386 1 5222610</phone>
      <email>franc.strle@kclj.si</email>
    </contact_backup>
    <investigator>
      <last_name>Petra Bogovic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katarina Ogrinc, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Ruzic-Sabljic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tjasa Cerar, Dipl Microbiol</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Franc Strle</investigator_full_name>
    <investigator_title>M.D., PhD</investigator_title>
  </responsible_party>
  <keyword>erythema migrans</keyword>
  <keyword>Lyme borreliosis</keyword>
  <keyword>ceftriaxone treatment</keyword>
  <keyword>doxycycline treatment</keyword>
  <keyword>outcome</keyword>
  <keyword>subjective symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythema</mesh_term>
    <mesh_term>Erythema Chronicum Migrans</mesh_term>
    <mesh_term>Glossitis, Benign Migratory</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 3, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

